Currently Viewing:
Supplements Measuring Persistency with Drug Therapy in Glaucoma Management
Participating Faculty
Introduction
Gail F. Schwartz, MD
An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular Hypertension
William C. Stewart, MD; Jessica Leech, BS; Elizabeth D. Sharpe, MD; John Kulze, MD; John Ellyn, MD; Douglas G. Day, MD
Measuring Patient Persistency with Drug Therapy Using Methods for the Design and Analysis of Natural History Studies
Eric S. Johnson, PhD; Essy Mozaffari, PharmD, MPH
Population-Based Persistency Rates for Topical Glaucoma Medications Measured with Pharmacy Claims Data
Samaresh Dasgupta, MHS; Vikki Oates, MAS; Brahim K. Bookhart, MBA; Baze Vaziri, MBA, CPA; Gail F. Schwartz, MD; Essy Mozaffari, PharmD, MPH
Rates of Discontinuation and Change of Glaucoma Therapy in a Managed Care Setting
Joshua J. Spooner, PharmD; Michael F. Bullano, PharmD; Laurence I. Ikeda, MD; Tara R. Cockerham, PharmD; William J. Waugh, PharmD; Thomas Johnson, Pha
Currently Reading
Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care Population
Fadia T. Shaya, PhD, MPH; C. Daniel Mullins, PhD; Winston Wong, PharmD; Jeannie Cho, PharmD

Dicontinuation Rates of Topical Glaucoma Medications in a Managed Care Population

Fadia T. Shaya, PhD, MPH; C. Daniel Mullins, PhD; Winston Wong, PharmD; Jeannie Cho, PharmD
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up